Montmorillonite

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Montmorillonite is a purified clay indicated in the treatment of intestinal pain and diarrhea.

Generic Name
Montmorillonite
DrugBank Accession Number
DB13654
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 360.307
Monoisotopic: 359.8254086
Chemical Formula
Al2H2O12Si4
Synonyms
  • Diosmectite
  • Montmorillonite
  • Montmorrillonite

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CarbamazepineMontmorillonite can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Montmorillonite.
Cholic AcidThe serum concentration of Cholic Acid can be decreased when it is combined with Montmorillonite.
DeferasiroxMontmorillonite can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dehydrocholic acidThe serum concentration of Dehydrocholic acid can be decreased when it is combined with Montmorillonite.
Deoxycholic acidThe serum concentration of Deoxycholic acid can be decreased when it is combined with Montmorillonite.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Montmorillonite.
EltrombopagMontmorillonite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy.
HalofantrineMontmorillonite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MephenytoinMontmorillonite can cause a decrease in the absorption of Mephenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
FOTAGEL SUSPENSION 3g/20ml (DIOCTAHEDRAL SMECTITE)SuspensionOralIMEKS PHARMA SDN. BHD.2020-09-08Not applicableMalaysia flag
hovid Diosmectite Oral Suspension 1g/10mLSuspensionOralHovid Berhad2020-09-08Not applicableMalaysia flag
Smecta Orange-Vanilla Flavour Powder for Oral Suspension 3gPowder, for suspensionOralEP PLUS GROUP SDN. BHD.2020-09-08Not applicableMalaysia flag
Smecta Strawberry Flavour Powder for Oral Suspension 3gPowder, for suspensionOralEP PLUS GROUP SDN. BHD.2020-09-08Not applicableMalaysia flag
SmectaGo 3g Oral Suspension In SachetSuspensionOralEP PLUS GROUP SDN. BHD.2020-09-08Not applicableMalaysia flag

Categories

ATC Codes
A07BC05 — Diosmectite
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as post-transition metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal organides
Sub Class
Post-transition metal oxides
Direct Parent
Post-transition metal oxides
Alternative Parents
Post-transition metal salts / Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Inorganic metalloid salt / Inorganic oxide / Inorganic post-transition metal salt / Inorganic salt / Post-transition metal oxide
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
A3N5ZCN45C
CAS number
1318-93-0
InChI Key
GUJOJGAPFQRJSV-UHFFFAOYSA-N
InChI
InChI=1S/2Al.4O2Si.H2O.3O/c;;4*1-3-2;;;;/h;;;;;;1H2;;;/q2*+3;;;;;;3*-2
IUPAC Name
dialuminium(3+) ion tetrakis(silanedione) hydrate trioxidandiide
SMILES
O.[O--].[O--].[O--].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O

References

General References
  1. FDA Thailand Product Information: Dehecta (dioctahedral smectite) oral solution [Link]
  2. AIFA: Diosmectal (Montmorillonite) Oral Powder for Suspension [Link]
ChemSpider
32699070
RxNav
1425919
Wikipedia
Montmorillonite

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBerberine / Coronavirus Disease 2019 (COVID‑19)1
4CompletedTreatmentDiarrhoea1
4CompletedTreatmentDiarrhoea;Acute1
4CompletedTreatmentGastroesophageal Reflux in Neonates1
3CompletedTreatmentDiarrhoea2
3TerminatedTreatmentHigh Output Stoma1
2WithdrawnTreatmentMalignancies1
2, 3RecruitingPreventionBreast Cancer1
1CompletedOtherChronic Functional Diarrhea of Unknown Origin1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for suspensionOral3 g
Powder, for solutionOral78.97 g
Powder, for solutionOral
Powder, for solutionOral3000 mg
PowderOral3 g
SuspensionOral
SuspensionOral10 g
Powder, for suspensionOral
PowderOral
Powder, for solutionOral3 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.66ChemAxon
pKa (Strongest Basic)-8.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity2.89 m3·mol-1ChemAxon
Polarizability3.28 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 20:46 / Updated on May 29, 2021 18:12